

Daftar Pustaka

- Adham, M. *et al.* (2012) 'Nasopharyngeal carcinoma in Indonesia: epidemiology, Incidence, sign, and symptoms at presentation', *Chin J Cancer*, 31(4), pp. 185–96.
- Adham, M. (2018) 'Nasopharyngeal Carcinoma Understanding the Anatomy, Ebv Marker, and Clinical Presentation', in Farhat (ed.) *Scientific Paper Compilation 1 st National Conference of Nasopharyngeal Carcinoma 'Prevention is Better than Cure'*. Medan: USU Press, pp. 6–65.
- AJCC (2018) *8th AJCC Cancer Staging Form Supplement 6-2018 update, AJCC Cancer Staging Manual, 8th Ed.* doi: 10.1016/j.aquaeng.2010.03.002.
- Bach, D. H. *et al.* (2017) 'The role of exosomes and miRNAs in drug-resistance of cancer cells', *International Journal of Cancer*, 141(2), pp. 220–230. doi: 10.1002/ijc.30669.
- Bray, F. *et al.* (2018) 'Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.', *CA: a cancer journal for clinicians*, 68(6), pp. 394–424. doi: 10.3322/caac.21492.
- Brzeszczyńska, J. *et al.* (2020) 'Validation of Reference Genes for Gene Expression Studies by RT-qPCR in HepaRG Cells during Toxicity Testing and Disease Modelling', *Cells*, 9(3), p. 770. doi: 10.3390/cells9030770.
- Burdakov, V. S. *et al.* (2018) 'Exosomes Transfer p53 between Cells and Can Suppress Growth and Proliferation of p53-Negative Cells', *Cell and Tissue Biology*, 12(1), pp. 20–26. doi: 10.1134/S1990519X18010030.
- Camacho, L., Guerrero, P. and Marchetti, D. (2013) 'MicroRNA and Protein Profiling of Brain Metastasis Competent Cell-Derived Exosomes', *PLoS ONE*, 8(9). doi: 10.1371/journal.pone.0073790.
- Chakrani, F. *et al.* (1995) 'Mutations clustered in exon 5 of the p53 gene in primary nasopharyngeal carcinomas from Southeastern Asia',

- International Journal of Cancer*, 61(3), pp. 316–320. doi: 10.1002/ijc.2910610307.
- Chalian, A. and Litman, D. (2006) 'Neoplasms of the nose and paranasal sinuses', in Snow Jr, J. B. and Ballenger, J. J. (eds) *Ballenger's Otorhinolaryngology Head and Neck Surgery*. 16th edn. Ontario: BC Decker, pp. 807–827. doi: 10.1017/CBO9780511545764.020.
- Chang, E. T. and Adami, H. O. (2006) 'The enigmatic epidemiology of nasopharyngeal carcinoma', *Cancer Epidemiology Biomarkers and Prevention*, 15(10), pp. 1765–1777. doi: 10.1158/1055-9965.EPI-06-0353.
- Cooks, T. *et al.* (2018) 'Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246', *Nature Communications*, 9(1). doi: 10.1038/s41467-018-03224-w.
- Effert, P. *et al.* (1992) 'Alterations of the p53 gene in nasopharyngeal carcinoma', *J Virol.*, 66(6), pp. 3768–3775.
- Gallo, A. *et al.* (2017) 'Global profiling of viral and cellular non-coding RNAs in Epstein–Barr virus-induced lymphoblastoid cell lines and released exosome cargos', *Cancer Letters*. Elsevier Ltd, 388, pp. 334–343. doi: 10.1016/j.canlet.2016.12.003.
- Haleshappa, R. *et al.* (2017) 'Epidemiology and outcomes of nasopharyngeal carcinoma: Experience from a regional cancer center in Southern India', *South Asian Journal of Cancer*, 6(3), p. 122. doi: 10.4103/2278-330x.214578.
- Harmati, M. *et al.* (2017) 'Stressors alter intercellular communication and exosome profile of nasopharyngeal carcinoma cells', *Journal of Oral Pathology and Medicine*, 46(4), pp. 259–266. doi: 10.1111/jop.12486.
- He, C. *et al.* (2017) 'The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma', *Cancer Biology and Therapy*. Taylor & Francis, 18(11), pp. 888–894. doi: 10.1080/15384047.2017.1281493.
- Herdini, C. (2018) 'Rigid nasopharyngoscopy and flexible endoscopy evaluation for diagnosis and recurrent nasopharyngeal carcinoma', in

Farhat (ed.) *Scientific Paper Compilation 1 st National Conference of Nasopharyngeal Carcinoma 'Prevention is Better than Cure'*. Medan: USU Press, pp. 72–78.

Hu, J. *et al.* (2020) 'Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy', *Theranostics*, 10(26), pp. 11921–11937. doi: 10.7150/thno.46006.

Huang, D. *et al.* (2017) 'MiR-20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells', *Cancer Cell International*. BioMed Central, 17(1), pp. 1–11. doi: 10.1186/s12935-017-0389-7.

Indrasari, S. R. *et al.* (2016) 'Clinical Study on Photodynamic Therapy (PDT) In Patients with Nasopharyngeal Carcinoma in Yogyakarta Review of Life Expectancy and Cytokine Level', *Journal of Otolaryngology-ENT Research*, 4(6), pp. 1–11. doi: 10.15406/joentr.2016.04.00120.

Jella, K. *et al.* (2018) 'Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy', *Vaccines*, p. 69. doi: 10.3390/vaccines6040069.

Kadriyan, H. (2018) 'FNAB's and incisional biopsy on nasopharyngeal cancer', in Farhat (ed.) *Scientific Paper Compilation 1 st National Conference of Nasopharyngeal Carcinoma 'Prevention is Better than Cure'*. Medan: USU Press, pp. 117–123.

Kadriyan, H. *et al.* (2018) 'Profile of Nasopharyngeal Carcinoma in West Nusa Tenggara , Indonesia The opportunity to explored several characteristic 1 . Department of Otolaryngology Head and Neck Surgery Medical Faculty , Mataram 2 . Department of Pathology Anatomy , Medical Faculty', in *Challenges and opportunities in public health and biomedical research; the asian perspective*. Okinawa.

Kadriyan, H., Sulaksana, Muhammad Alfian, *et al.* (2019) 'Evaluation of renal function before and after chemotherapy in nasopharyngeal carcinoma in Lombok', *International Journal on Nasopharyngeal Cancer*,

01(1), pp. 10–11. doi: 10.32734/ijnpc.v.1i1.951.

Kadriyan, H., Sulaksana, Mochammad Alfian, *et al.* (2019) 'Incidence and characteristics of anemia among patients with nasopharyngeal carcinoma in Lombok, Indonesia', *AIP Conference Proceedings*, 2199(December), pp. 0700151–0700156. doi: 10.1063/1.5141329.

Karki, R. *et al.* (2015) 'Defining "mutation" and "polymorphism" in the era of personal genomics', *BMC Medical Genomics*. *BMC Medical Genomics*, 8(1), pp. 1–7. doi: 10.1186/s12920-015-0115-z.

Keryer-Bibens, C. *et al.* (2006) 'Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9', *BMC Cancer*, 6, pp. 1–8. doi: 10.1186/1471-2407-6-283.

Kobayashi, E. *et al.* (2018) 'C-Terminal Farnesylation of UCH-L1 Plays a Role in Transport of Epstein-Barr Virus Primary Oncoprotein LMP1 to Exosomes', *mSphere*, 3(1), pp. 1–15. doi: 10.1128/msphere.00030-18.

Komite Penanggulangan Kanker Nasional (2017) *Pedoman Nasional Pelayanan Kedokteran; Kanker Nasofaring*. Jakarta: Kementerian Kesehatan Republik Indonesia. Available at: <http://www.kanker.kemendes.go.id>.

König, L. *et al.* (2018) 'Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy', *Oncotarget*. Taylor & Francis, 7(1), pp. 1–9. doi: 10.1080/2162402X.2017.1376153.

Kurniawan, A. N. and Leong, A. S.-Y. (2000) 'p53 protein overexpression in nasopharyngeal carcinoma in Indonesian patients', *Medical Journal of Indonesia*, 9(September), p. 209. doi: 10.13181/mji.v9i3.636.

Lässer, C., Eldh, M. and Lötvall, J. (2012) 'Isolation and Characterization of RNA-Containing Exosomes', *Journal of Visualized Experiments*, (59), pp. 1–6. doi: 10.3791/3037.

Lee, A. W. M. *et al.* (2015) 'Management of nasopharyngeal carcinoma: Current practice and future perspective', *Journal of Clinical Oncology*, pp.

3356–3364. doi: 10.1200/JCO.2015.60.9347.

Lespagnol, A. *et al.* (2008) 'Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice', *Cell Death and Differentiation*, 15(11), pp. 1723–1733. doi: 10.1038/cdd.2008.104.

Liu, Junjie *et al.* (2019) 'Prognostic value of the Epstein–Barr virus and tumor suppressor gene p53 gene in nasopharyngeal squamous cell carcinoma', *Journal of Cancer Research and Therapeutics*, 15, pp. 426–436. doi: 10.4103/jcrt.JCRT_750_18.

Liu, Juan *et al.* (2019) 'Tumor suppressor p53 and metabolism', *Journal of Molecular Cell Biology*, 11(4), pp. 284–292. doi: 10.1093/jmcb/mjy070.

Liu, L. *et al.* (2019) 'Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma', *Cancer Medicine*, 8(6), pp. 3142–3151. doi: 10.1002/cam4.2185.

Makovec, T. (2019) 'Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy', *Radiology and Oncology*, 53(2), pp. 148–158. doi: 10.2478/raon-2019-0018.

Malla, B. *et al.* (2017) 'Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy', *International Journal of Radiation Oncology Biology Physics*. Elsevier Inc., 98(5), pp. 982–995. doi: 10.1016/j.ijrobp.2017.03.031.

Martin, A. C. R. *et al.* (2002) 'Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein', *Human Mutation*, 19(2), pp. 149–164. doi: 10.1002/humu.10032.

Mathivanan, S. *et al.* (2012) 'ExoCarta 2012: Database of exosomal proteins, RNA and lipids', *Nucleic Acids Research*, 40(D1), pp. 1241–1244. doi: 10.1093/nar/gkr828.

Mrizak, D. *et al.* (2015) 'Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells', *Journal of the National Cancer Institute*, 107(1), pp. 1–13. doi: 10.1093/jnci/dju363.

- Munich, S. *et al.* (2012) 'Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands', *Oncolmmunology*, 1(7), pp. 1074–1083. doi: 10.4161/onci.20897.
- Mutschelknaus, L. *et al.* (2016) 'Exosomes derived from squamous head and neck cancer promote cell survival after ionizing radiation', *PLoS ONE*, 11(3), pp. 1–16. doi: 10.1371/journal.pone.0152213.
- Mutschelknaus, L. (2017) *Functional analysis of head and neck cancer exosomes released in response to ionizing radiation*.
- Nakagawara, A. and Ozaki, T. (2011) 'P53: The attractive tumor suppressor in the cancer research field', *Journal of Biomedicine and Biotechnology*, 2011, pp. 28–30. doi: 10.1155/2011/603925.
- Nakanishi, Y. *et al.* (2017) 'Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma', *Cancer and Metastasis Reviews*. *Cancer and Metastasis Reviews*, 36(3), pp. 435–447. doi: 10.1007/s10555-017-9693-x.
- NCCN (2018) *Head and Neck Cancer, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)*. doi: 10.1615/critrevoncog.v23.i3-4.10.
- Peng, H. *et al.* (2018) 'Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A big-data, intelligence platform-based analysis', *BMC Cancer*. *BMC Cancer*, 18(1), pp. 1–9. doi: 10.1186/s12885-018-4268-y.
- Qin, Z. Q. *et al.* (2020) 'Heterozygous p53-R280T Mutation Enhances the Oncogenicity of NPC Cells Through Activating PI3K-Akt Signaling Pathway', *Frontiers in Oncology*, 10(February), pp. 1–14. doi: 10.3389/fonc.2020.00104.
- Ren, J. *et al.* (2016) 'From structures to functions: Insights into exosomes as promising drug delivery vehicles', *Biomaterials Science*. Royal Society of Chemistry, 4(6), pp. 910–921. doi: 10.1039/c5bm00583c.
- Roma-Rodrigues, C., Fernandes, A. R. and Baptista, P. V. (2014) 'Exosome in Tumour Microenvironment: Overview of the Crosstalk between Normal and Cancer Cells', *BioMed Research International*.

Hindawi Publishing Corporation, 2014, pp. 1–10. doi:

10.1155/2014/179486.

Sharma, T. D. *et al.* (2011) 'Nasopharyngeal carcinoma--a clinico-pathological study in a regional cancer centre of northeastern India.', *Asian Pacific journal of cancer prevention : APJCP*, 12(6), pp. 1583–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22126503>.

Shi, S. *et al.* (2016) 'Mesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression', *American Journal of Cancer Research*, 6(2), pp. 459–472.

Sigal, A. and Rotter, V. (2000) 'Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.', *Cancer research*, 60(24), pp. 6788–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11156366>.

Stevic, I., Buescher, G. and Ricklefs, F. L. (2020) 'Monitoring Therapy Efficiency in Cancer through Extracellular Vesicles', *Cells*, 9(1), p. 130. doi: 10.3390/cells9010130.

Stoker, S. D. *et al.* (2014) 'A prospective study: Current problems in radiotherapy for nasopharyngeal carcinoma in Yogyakarta, Indonesia', *PLoS ONE*, 9(1), p. e85959. doi: 10.1371/journal.pone.0085959.

Suwondo, S., Surarso, B. and Kristyono, I. (2018) 'Biopsy Examination Validity Based on Narrow Band Imaging Guidance of Nasopharyngeal Carcinoma Suspected Patients', *Indian Journal of Otolaryngology and Head and Neck Surgery*. Springer India, pp. 1–5. doi: 10.1007/s12070-018-1324-5.

Szajnik, M. *et al.* (2010) 'Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg)', *PLoS ONE*, 5(7). doi: 10.1371/journal.pone.0011469.

Theodoraki, M. N. *et al.* (2019) 'Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT', *Oncolmmunology*, 8(7). doi: 10.1080/2162402X.2019.1593805.

- Tulalamba, W. and Janvilisri, T. (2012) 'Nasopharyngeal carcinoma signaling pathway: An update on molecular biomarkers', *International Journal of Cell Biology*, 2012. doi: 10.1155/2012/594681.
- Wan, Z. *et al.* (2018) 'Exosome-mediated cell-cell communication in tumor progression.', *American journal of cancer research*, 8(9), pp. 1661–1673. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/30323961>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6176174>.
- Xiang, X. *et al.* (2009) 'Induction of myeloid-derived suppressor cells by tumor exosome', *International Journal of Cancer*, 124(11), pp. 2621–2633. doi: 10.1002/ijc.24249.Induction.
- Yan, H. *et al.* (2017) 'CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma', *Journal of Cancer*, 8(11). doi: 10.7150/jca.19078.
- Yang, J. K. *et al.* (2017) 'DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme', *Therapeutic Advances in Medical Oncology*, 9(12), pp. 741–754. doi: 10.1177/1758834017737471.
- Yang, X. R. *et al.* (2005) 'Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan', *Cancer Epidemiology Biomarkers and Prevention*, 14(4), pp. 900–905. doi: <http://dx.doi.org/10.1158/1055-9965.EPI-04-0680>.
- Ye, S. *et al.* (2014) 'Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma', *Oncotarget*, 5(14). doi: 10.18632/oncotarget.2118.
- Ye, S. B. *et al.* (2016) 'Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma', *Journal of Pathology*, pp. 329–340. doi: 10.1002/path.4781.
- Yusuf, M. *et al.* (2018) 'Ekspresi protein P53 dan HSP70 pada sel punca

- karsinoma nasofaring yang resisten terhadap radioterapi', *Oto Rhino Laryngologica Indonesiana*, 44(2), p. 122. doi: 10.32637/orli.v44i2.93.
- Zhang, H. *et al.* (2017) 'Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis', *Nature Communications*, 8(May 2016). doi: 10.1038/ncomms15016.
- Zhang, P. *et al.* (2015) 'p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study', *Oncology Letters*, 9(1), pp. 1509–1514. doi: 10.3892/ol.2014.2631.
- Zhang, Z. *et al.* (2019) 'LMP1-positive extracellular vesicles promote radioresistance in nasopharyngeal carcinoma cells through P38 MAPK signaling', *Cancer Medicine*, 8(13), pp. 6082–6094. doi: 10.1002/cam4.2506.
- Zhou, Y. *et al.* (2018) 'Exosomes in nasopharyngeal carcinoma', *Journal of Cancer*, 9(5), pp. 767–777. doi: 10.7150/jca.22505.
- Zihlif, M. A. *et al.* (2013) 'Thymoquinone efficiently inhibits the survival of EBV-infected B cells and alters EBV gene expression', *Integrative Cancer Therapies*, 12(3), pp. 257–263. doi: 10.1177/1534735412458827.

Lampiran 1 : Daftar tilik data epidemiologi dan klinis

Nama penderita :

No. rekam medik :

Umur :

Jenis Kelamin :

Alamat :

Keluhan utama :

Lama keluhan tsb dialami :

Keluhan lain :

Pemeriksaan klinis :

Pemeriksaan Endoskopi :

Pemeriksaan CT scan/MRI:

Hasil Pemeriksaan PA :

Diagnosis :

Stadium :

Pengobatan :

Jenis Kemoterapi :

Radioterapi :

Tgl mulai kemoradiasi :

Tgl selesai kemoradiasi :

Hasil pemeriksaan Eksosom sebelum kemoradiasi :

Hasil pemeriksaan Eksosom setelah kemoradiasi :

Hasil pemeriksaan ELISA p53 sebelum kemoradiasi :

Hasil pemeriksaan ELISA p53 setelah kemoradiasi :

Lampiran 2. Lembar persetujuan mengikuti penelitian

Bapak/ibu/saudara/i yang terhormat, terima kasih atas kesediaan waktunya untuk berperan sebagai sampel (subjek) pada penelitian ini. Penelitian ini berjudul “Analisis ekspresi eksosom RNA dan hubungannya dengan kadar p53 pada penderita kanker nasofaring”. Penelitian ini bertujuan untuk memperoleh data tentang ekspresi eksosom dan protein p53 pada serum penderita kanker nasofaring sebelum dan sesudah menjalani kemoradiasi. Manfaat penelitian ini adalah untuk menentukan hubungan antara eksosom dan protein p53 yang nantinya dapat digunakan sebagai alat bantu dalam diagnosis, pengobatan maupun pemantauan pasien kanker nasofaring.

Dalam penelitian ini, Bapak/ibu/saudara/i akan diminta memberikan izin untuk penggunaan serum yang diambil dari darah vena sebelum dimulainya kemoradiasi dan setelah kemoradiasi, kemudian dilakukan analisis lebih lanjut di laboratorium. Berdasarkan hal tersebut, risiko komplikasi yang timbul dari pengumpulan sampel tersebut sangat kecil seperti lebam di daerah penagmbilan darah atau infeksi. Selain itu, akan dilakukan juga wawancara ringkas dengan panduan cek list untuk mengetahui beberapa faktor terkait kanker nasofaring yang dialami oleh bapak/ibu, termasuk data hasil PA dan CT scan/MRI akan didokumentasikan untuk mengetahui jenis dan stadium tumornya. Data yang diperoleh dari penelitian ini bersifat rahasia dan hanya digunakan untuk keperluan penelitian ini saja.

Bapak/ibu/saudara/i berhak untuk menolak berpartisipasi atau tidak melanjutkan partisipasi dalam penelitian ini tanpa konsekuensi apapun. Bila terdapat hal-hal yang masih kurang jelas, Bapak/ibu/saudara/i dapat menghubungi tim peneliti (dr. Hamsu Kadriyan, SpTHT-KL (K) dengan no. Hp: 0818366217).

Dengan menandatangani formulir ini saya menyatakan setuju untuk mengikuti penelitian ini.

Mataram, Juni, 2019

Lampiran 3. Lembar penilaian status fisik penderita (indeks Karnofsky)

Nama Penderita :

No. RM :

Nilai Skala :

SKALA KARNOFSKY

100 = normal, tidak ada keluhan, tidak ada penyakit

90 = mampu aktivitas normal, tanda-tanda minimal penyakit

80 = aktivitas normal dengan sedikit kesukaran, beberapa tanda penyakit

70 = mampu menjalankan keperluan sendiri, tidak mampu menjalankan pekerjaan

60 = mampu menjalankan sebagian besar keperluan sendiri, selalu memerlukan bantuan

50 = memerlukan bantuan cukup banyak, juga pertolongan medis

40 = tidak mampu merawat diri sendiri, tidak dapat bekerja lagi

30 = sakit berat, indikasi perawatan di rumah sakit

20 = sakit sangat berat

10 = Sekarat

0 = mati




Skala penilaian

0-40 = Jelek

50-80 = sedang

80-100 = Baik









Lampiran 4. Persetujuan Kelayakan Etik



























KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN KESEHATAN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, MMed,PhD, SpGK, TELP. 081241850858, 0411 5780103, Fax : 0411-581431			
REKOMENDASI PERSETUJUAN ETIK Nomor : 53/UN4.6.4.5.31/ PP36/ 2020			
			Tanggal: 22 Januari 2020
Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :			
No Protokol	UH19090667	No Sponsor Protokol	
Peneliti Utama	dr. Hamsu Kadriyan, Sp.THT-KL	Sponsor	
Judul Peneliti	Analisis Ekspresi Eksosom RNA dan Hubungannya Dengan Ekspresi p53 Pada Penderita Kanker Nasofaring		
No Versi Protokol	2	Tanggal Versi	17 Januari 2020
No Versi PSP	2	Tanggal Versi	17 Januari 2020
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo Makassar dan RSUD Propinsi NTB		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 9 Oktober 2019	Masa Berlaku 22 Januari 2020 sampai 22 Januari 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	
Kewajiban Peneliti Utama:			
<ul style="list-style-type: none"> Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah Menyerahkan laporan akhir-setelah Penelitian berakhir Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation) Mematuhi semua peraturan yang ditentukan 			






























Lampiran 5. Hasil RT-PCR

<input type="checkbox"/>	Tube	Style	Sample name	Sample type	Assay	Assay result	Target	Cq	Take-off	Eff.
<input checked="" type="checkbox"/>	1		p53-1 10 A	Sample	--	--	Green	26,68	27,00	2,09
<input checked="" type="checkbox"/>	2		p53-1 10 B	Sample	--	--	Green	25,60	26,00	2,11
<input checked="" type="checkbox"/>	3		p53-1 11 A	Sample	--	--	Green	26,30	26,90	2,08
<input checked="" type="checkbox"/>	4		p53-1 11 B	Sample	--	--	Green	23,91	24,60	2,10
<input type="checkbox"/>	Tube	Style	Sample name	Sample type	Assay	Assay result	Target	Cq	Take-off	Eff.
<input checked="" type="checkbox"/>	2		1A P53-1	Sample	--	--	Green	27,76	28,40	2,13
<input checked="" type="checkbox"/>	3		1B P53-1	Sample	--	--	Green	30,79	31,80	2,12
<input checked="" type="checkbox"/>	4		3A P53-1	Sample	--	--	Green	31,36	32,20	2,09
<input checked="" type="checkbox"/>	5		3B P53-1	Sample	--	--	Green	31,27	32,20	2,11
<input checked="" type="checkbox"/>	6		4A P53-1	Sample	--	--	Green	27,97	28,60	2,10
<input checked="" type="checkbox"/>	7		4B P53-1	Sample	--	--	Green	30,07	31,20	2,08
<input checked="" type="checkbox"/>	8		10A P53-1	Sample	--	--	Green	29,98	30,80	2,14
<input checked="" type="checkbox"/>	9		10B P53-1	Sample	--	--	Green	28,47	29,20	2,08
<input checked="" type="checkbox"/>	10		11A P53-1	Sample	--	--	Green	30,28	31,20	2,13
<input checked="" type="checkbox"/>	11		11B P53-1	Sample	--	--	Green	28,44	29,10	2,10
<input checked="" type="checkbox"/>	12		NTC2 P53-1	NTC	--	--	Green	--	--	--
<input type="checkbox"/>	Tube	Style	Sample name	Sample type	Assay	Assay result	Target	Cq	Take-off	Eff.
<input checked="" type="checkbox"/>	1		1A P53-1 a	Sample	--	--	Green	29,64	29,80	2,09
<input checked="" type="checkbox"/>	2		1B P53-1 a	Sample	--	--	Green	29,05	29,20	2,09
<input checked="" type="checkbox"/>	3		3 A P53-1 a	Sample	--	--	Green	30,71	31,40	2,08
<input checked="" type="checkbox"/>	4		3B P53-1 a	Sample	--	--	Green	31,58	32,10	2,11
<input checked="" type="checkbox"/>	5		4A P53-1 a	Sample	--	--	Green	28,38	28,50	2,12
<input checked="" type="checkbox"/>	6		4B P53-1 a	Sample	--	--	Green	29,70	29,90	2,11
<input checked="" type="checkbox"/>	7		1A P53-1 b	Sample	--	--	Green	27,72	27,90	2,11
<input checked="" type="checkbox"/>	8		1B P53-1 b	Sample	--	--	Green	30,42	30,90	2,15
<input checked="" type="checkbox"/>	9		3A P53-1 b	Sample	--	--	Green	31,35	31,90	2,13
<input checked="" type="checkbox"/>	10		3B P53-1 b	Sample	--	--	Green	30,49	31,00	2,12
<input checked="" type="checkbox"/>	11		4A P53-1 b	Sample	--	--	Green	32,31	32,50	2,12
<input checked="" type="checkbox"/>	12		4B P53-1 b	Sample	--	--	Green	29,13	29,40	2,09
<input checked="" type="checkbox"/>	13		10 A P53-1	Sample	--	--	Green	26,28	26,30	2,11
<input checked="" type="checkbox"/>	14		10 B P53-1	Sample	--	--	Green	27,36	27,50	2,14
<input checked="" type="checkbox"/>	15		11A P53-1	Sample	--	--	Green	29,44	29,60	2,14
<input checked="" type="checkbox"/>	16		11B P53-1	Sample	--	--	Green	28,10	28,30	2,10
<input checked="" type="checkbox"/>	17		14 A P53-1 a	Sample	--	--	Green	26,21	26,40	2,09
<input checked="" type="checkbox"/>	18		14 B P53-1 a	Sample	--	--	Green	28,42	28,50	2,13
<input checked="" type="checkbox"/>	19		15 A P53-1 a	Sample	--	--	Green	31,84	32,20	2,07
<input checked="" type="checkbox"/>	20		15 B P53-1 a	Sample	--	--	Green	32,11	32,50	2,13
<input checked="" type="checkbox"/>	21		17 A P53-1 a	Sample	--	--	Green	33,06	32,50	2,10
<input checked="" type="checkbox"/>	22		17 B P53-1 a	Sample	--	--	Green	32,69	32,50	2,12
<input checked="" type="checkbox"/>	23		14 A P53-1 b	Sample	--	--	Green	31,17	31,60	2,13
<input checked="" type="checkbox"/>	24		14 B P53-1 b	Sample	--	--	Green	29,01	29,30	2,10
<input checked="" type="checkbox"/>	25		15 A P53-1 b	Sample	--	--	Green	30,66	31,20	2,10
<input checked="" type="checkbox"/>	26		15 B P53-1 b	Sample	--	--	Green	31,28	31,90	2,10
<input checked="" type="checkbox"/>	27		17 A P53-1 b	Sample	--	--	Green	31,67	32,20	2,09
<input checked="" type="checkbox"/>	28		17 B P53-1 b	Sample	--	--	Green	32,62	32,50	2,12

























<input checked="" type="checkbox"/>	29		14 A P53-1 c	Sample	--	--	Green	30,64	31,10	2,09
<input checked="" type="checkbox"/>	30		14 B P53-1 c	Sample	--	--	Green	29,51	29,70	2,11
<input checked="" type="checkbox"/>	31		15 A P53-1 c	Sample	--	--	Green	35,50	32,40	1,99
<input checked="" type="checkbox"/>	32		15 B P53-1 c	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	33		17 A P53-1 c	Sample	--	--	Green	37,50	32,20	1,93
<input checked="" type="checkbox"/>	34		17 B P53-1 c	Sample	--	--	Green	31,14	31,70	2,13
<input checked="" type="checkbox"/>	5		p53-2 10 A	Sample	--	--	Green	28,26	28,50	2,10
<input checked="" type="checkbox"/>	6		p53-2 10 B	Sample	--	--	Green	29,60	30,00	2,09
<input checked="" type="checkbox"/>	37		p53-2 11 A	Sample	--	--	Green	26,68	27,40	2,13
<input checked="" type="checkbox"/>	38		p53-2 11 B	Sample	--	--	Green	27,02	27,70	2,07
<input checked="" type="checkbox"/>	12		NTC2 P53-2	NTC	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	26		1A P53-2	Sample	--	--	Green	26,34	27,40	2,10
<input checked="" type="checkbox"/>	27		1B P53-2	Sample	--	--	Green	26,88	28,00	2,10
<input checked="" type="checkbox"/>	28		3A P53-2	Sample	--	--	Green	27,68	28,70	2,13
<input checked="" type="checkbox"/>	29		3B P53-2	Sample	--	--	Green	26,18	27,30	2,11
<input checked="" type="checkbox"/>	30		4A P53-2	Sample	--	--	Green	24,83	26,00	2,09
<input checked="" type="checkbox"/>	31		4B P53-2	Sample	--	--	Green	26,81	27,90	2,10
<input checked="" type="checkbox"/>	32		10A P53-2	Sample	--	--	Green	28,38	29,40	2,17
<input checked="" type="checkbox"/>	33		10B P53-2	Sample	--	--	Green	25,91	27,10	2,07
<input checked="" type="checkbox"/>	34		11A P53-2	Sample	--	--	Green	26,68	27,70	2,12
<input checked="" type="checkbox"/>	35		11B P53-2	Sample	--	--	Green	26,94	28,10	2,12
<input type="checkbox"/>	Tube	Style	Sample name	Sample type	Assay	Assay result	Target	Cq	Take-off	Eff.
<input checked="" type="checkbox"/>	34		17 B P53-1 c	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	35		1A P53-2 a	Sample	--	--	Green	26,19	26,60	2,16
<input checked="" type="checkbox"/>	36		1B P53-2 a	Sample	--	--	Green	26,76	27,20	2,13
<input checked="" type="checkbox"/>	37		3 A P53-2 a	Sample	--	--	Green	27,10	27,50	2,16
<input checked="" type="checkbox"/>	38		3B P53-2 a	Sample	--	--	Green	27,31	27,80	2,16
<input checked="" type="checkbox"/>	39		4A P53-2 a	Sample	--	--	Green	26,27	26,70	2,14
<input checked="" type="checkbox"/>	40		4B P53-2 a	Sample	--	--	Green	27,26	27,70	2,16
<input checked="" type="checkbox"/>	41		1A P53-2 b	Sample	--	--	Green	26,46	26,90	2,14
<input checked="" type="checkbox"/>	42		1B P53-2 b	Sample	--	--	Green	26,89	27,40	2,14
<input checked="" type="checkbox"/>	43		3A P53-2 b	Sample	--	--	Green	27,72	28,10	2,11
<input checked="" type="checkbox"/>	44		3B P53-2 b	Sample	--	--	Green	28,07	28,50	2,17
<input checked="" type="checkbox"/>	45		4A P53-2 b	Sample	--	--	Green	25,38	25,90	2,14
<input checked="" type="checkbox"/>	46		4B P53-2 b	Sample	--	--	Green	26,73	27,30	2,14
<input checked="" type="checkbox"/>	47		10 A P53-2	Sample	--	--	Green	27,93	28,30	2,15
<input checked="" type="checkbox"/>	48		10 B P53-2	Sample	--	--	Green	26,47	27,00	2,15
<input checked="" type="checkbox"/>	49		11A P53-2	Sample	--	--	Green	27,29	27,70	2,15
<input checked="" type="checkbox"/>	50		11B P53-2	Sample	--	--	Green	27,17	27,70	2,15
<input checked="" type="checkbox"/>	51		14 A P53-2 a	Sample	--	--	Green	26,16	26,50	2,17
<input checked="" type="checkbox"/>	52		14 B P53-2 a	Sample	--	--	Green	26,74	27,40	2,14
<input checked="" type="checkbox"/>	53		15 A P53-2 a	Sample	--	--	Green	27,44	27,90	2,16
<input checked="" type="checkbox"/>	54		15 B P53-2 a	Sample	--	--	Green	27,29	27,80	2,18
<input checked="" type="checkbox"/>	54		15 B P53-2 a	Sample	--	--	Green	27,29	27,80	2,18
<input checked="" type="checkbox"/>	55		17 A P53-2 a	Sample	--	--	Green	27,42	27,90	2,15
<input checked="" type="checkbox"/>	56		17 B P53-2 a	Sample	--	--	Green	28,23	28,80	2,19
<input checked="" type="checkbox"/>	57		14 A P53-2 b	Sample	--	--	Green	25,42	25,90	2,11
<input checked="" type="checkbox"/>	58		14 B P53-2 b	Sample	--	--	Green	27,48	28,00	2,14
<input checked="" type="checkbox"/>	59		15 A P53-2 b	Sample	--	--	Green	26,91	27,40	2,12
<input checked="" type="checkbox"/>	60		15 B P53-2 b	Sample	--	--	Green	27,25	27,60	2,15
<input checked="" type="checkbox"/>	61		17 A P53-2 b	Sample	--	--	Green	28,03	28,50	2,15
<input checked="" type="checkbox"/>	62		17 B P53-2 b	Sample	--	--	Green	27,50	28,00	2,14
<input checked="" type="checkbox"/>	63		14 A P53-2 c	Sample	--	--	Green	24,96	25,40	2,11
<input checked="" type="checkbox"/>	64		14 B P53-2 c	Sample	--	--	Green	27,15	27,50	2,17
<input checked="" type="checkbox"/>	65		15 A P53-2 c	Sample	--	--	Green	26,81	27,30	2,15
<input checked="" type="checkbox"/>	66		15 B P53-2 c	Sample	--	--	Green	27,26	27,70	2,16
<input checked="" type="checkbox"/>	67		17 A P53-2 c	Sample	--	--	Green	27,90	28,30	2,13
<input checked="" type="checkbox"/>	68		17 B P53-2 c	Sample	--	--	Green	27,26	27,70	2,14
<input type="checkbox"/>	71		NTC p53-1	NTC	Sample	--	Green	--	--	--
<input checked="" type="checkbox"/>	72		NTC p53-2	NTC	--	--	Green	--	--	--












































		p53-3 10 A	Sample	--	--	Green	24,87	25,80	2,09
		p53-3 10 B	Sample	--	--	Green	25,01	25,90	2,08
		p53-3 11 A	Sample	--	--	Green	--	--	--
		p53-3 11 B	Sample	--	--	Green	--	--	--

	Tube	Style	Sample name	Sample type	Assay	Assay result	Target	Cq	Take-off	Eff.
<input checked="" type="checkbox"/>	1		NTC 1	NTC	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	2		1 A u1	Sample	--	--	Green	28,63	28,50	2,06
<input checked="" type="checkbox"/>	3		1 B u1	Sample	--	--	Green	27,73	27,60	2,09
<input checked="" type="checkbox"/>	4		3 A u1	Sample	--	--	Green	29,52	29,50	2,06
<input checked="" type="checkbox"/>	5		3 B u1	Sample	--	--	Green	26,25	26,20	2,06
<input checked="" type="checkbox"/>	6		4 A u1	Sample	--	--	Green	25,58	25,50	2,11
<input checked="" type="checkbox"/>	7		4 B u1	Sample	--	--	Green	29,62	29,60	2,05
<input checked="" type="checkbox"/>	8		10 A u1	Sample	--	--	Green	30,91	31,40	2,04
<input checked="" type="checkbox"/>	9		10 B u1	Sample	--	--	Green	25,07	25,20	2,08
<input checked="" type="checkbox"/>	10		11 A u1	Sample	--	--	Green	30,66	31,00	2,01
<input checked="" type="checkbox"/>	11		11 B u1	Sample	--	--	Green	28,25	28,40	2,08
<input checked="" type="checkbox"/>	12		14 A u1	Sample	--	--	Green	23,67	23,50	2,09
<input checked="" type="checkbox"/>	13		14 B u1	Sample	--	--	Green	27,04	26,90	2,05
<input type="checkbox"/>	14		15 A u1	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	15		15 B u1	Sample	--	--	Green	29,74	29,70	2,06
<input checked="" type="checkbox"/>	16		17 A u1	Sample	--	--	Green	32,94	32,50	2,07
<input checked="" type="checkbox"/>	17		17 B u1	Sample	--	--	Green	28,71	28,70	2,02
<input checked="" type="checkbox"/>	18		1 A u2	Sample	--	--	Green	26,39	26,40	2,08
<input checked="" type="checkbox"/>	19		1 B u2	Sample	--	--	Green	29,50	29,50	2,09
<input checked="" type="checkbox"/>	20		3 A u2	Sample	--	--	Green	28,84	28,80	2,02
<input checked="" type="checkbox"/>	21		3 B u2	Sample	--	--	Green	27,84	27,90	2,05
<input checked="" type="checkbox"/>	22		4 A u2	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	23		4 B u2	Sample	--	--	Green	30,91	31,30	2,04
<input checked="" type="checkbox"/>	24		10 A u2	Sample	--	--	Green	30,77	31,20	2,00
<input checked="" type="checkbox"/>	25		10 B u2	Sample	--	--	Green	25,22	25,30	2,08

<input checked="" type="checkbox"/>	37		NTC 2	NTC	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	38		11 A u2	Sample	--	--	Green	35,28	32,40	2,17
<input checked="" type="checkbox"/>	39		11 B u2	Sample	--	--	Green	27,15	27,20	2,04
<input checked="" type="checkbox"/>	40		14 A u2	Sample	--	--	Green	23,33	23,30	2,09
<input checked="" type="checkbox"/>	41		14 B u2	Sample	--	--	Green	24,16	24,10	2,05
<input checked="" type="checkbox"/>	42		15 A u2	Sample	--	--	Green	28,87	28,70	2,04
<input checked="" type="checkbox"/>	43		15 B u2	Sample	--	--	Green	29,77	29,90	2,04
<input checked="" type="checkbox"/>	44		17 A u2	Sample	--	--	Green	30,53	30,90	2,06
<input checked="" type="checkbox"/>	45		17 B u2	Sample	--	--	Green	30,30	30,60	2,06
<input checked="" type="checkbox"/>	46		1 A u3	Sample	--	--	Green	25,79	25,80	2,08
<input checked="" type="checkbox"/>	47		1 B u3	Sample	--	--	Green	36,67	27,80	1,79
<input checked="" type="checkbox"/>	48		3 A u3	Sample	--	--	Green	28,63	28,70	2,04
<input checked="" type="checkbox"/>	49		3 B u3	Sample	--	--	Green	28,94	29,00	2,04
<input checked="" type="checkbox"/>	50		4 A u3	Sample	--	--	Green	24,92	25,00	2,05
<input checked="" type="checkbox"/>	51		4 B u3	Sample	--	--	Green	29,96	30,30	2,02
<input checked="" type="checkbox"/>	52		10 A u3	Sample	--	--	Green	30,79	31,20	2,01
<input checked="" type="checkbox"/>	53		10 B u3	Sample	--	--	Green	26,60	26,50	2,07
<input checked="" type="checkbox"/>	54		11 A u3	Sample	--	--	Green	29,53	29,50	2,06
<input checked="" type="checkbox"/>	55		11 B u3	Sample	--	--	Green	27,74	27,80	2,04
<input checked="" type="checkbox"/>	56		14 A u3	Sample	--	--	Green	22,45	22,50	2,03
<input checked="" type="checkbox"/>	57		14 B u3	Sample	--	--	Green	25,93	26,00	2,03
<input checked="" type="checkbox"/>	58		15 A u3	Sample	--	--	Green	27,86	28,00	2,02
<input checked="" type="checkbox"/>	59		15 B u3	Sample	--	--	Green	34,12	32,40	2,01
<input checked="" type="checkbox"/>	60		17 A u3	Sample	--	--	Green	32,99	32,40	2,09
<input checked="" type="checkbox"/>	61		17 B u3	Sample	--	--	Green	29,83	30,10	2,00
	26		1 B GADPH	Sample	--	--	Green	30,77	30,20	1,98
	27		4 A GADPH	Sample	--	--	Green	25,25	24,60	2,09
	37		NTC 2	NTC	--	--	Green	--	--	--
	62		15 A GADPH	Sample	--	--	Green	28,28	27,60	2,14

Green

Tube	Style	Sample name	Sample type	Assay	Assay result	Target	Cq	Take-off	Eff.
2		1 A u1	Sample	--	--	Green	34,37	32,50	2,09
3		1 B u1	Sample	--	--	Green	32,92	32,30	2,09
4		3 A u1	Sample	--	--	Green	--	--	--
5		3 B u1	Sample	--	--	Green	--	--	--
6		4 A u1	Sample	--	--	Green	32,69	32,10	2,07
7		4 B u1	Sample	--	--	Green	35,20	32,30	2,09
8		10 A u1	Sample	--	--	Green	36,23	32,20	2,15
9		10 B u1	Sample	--	--	Green	35,09	32,40	2,09
10		11 A u1	Sample	--	--	Green	31,77	31,30	2,04
11		11 B u1	Sample	--	--	Green	35,03	32,40	2,07
12		14 A u1	Sample	--	--	Green	32,99	32,30	2,09
13		14 B u1	Sample	--	--	Green	35,70	32,30	2,06
14		15 A u1	Sample	--	--	Green	--	--	--
15		15 B u1	Sample	--	--	Green	--	--	--
16		17 A u1	Sample	--	--	Green	--	--	--
17		17 B u1	Sample	--	--	Green	--	--	--
18		1 A u2	Sample	--	--	Green	32,60	32,10	2,05
19		1 B u2	Sample	--	--	Green	34,65	32,40	2,04
20		3 A u2	Sample	--	--	Green	34,12	32,40	2,11
21		3 B u2	Sample	--	--	Green	36,54	32,20	2,14
22		4 A u2	Sample	--	--	Green	38,13	32,30	1,81
23		4 B u2	Sample	--	--	Green	--	--	--
24		10 A u2	Sample	--	--	Green	--	--	--
25		10 B u2	Sample	--	--	Green	38,10	32,20	3,17

37		NTC 2	NTC	--	--	Green	--	--	--	
38		11 A u2	Sample	--	--	Green	33,76	32,40	2,08	
39		11 B u2	Sample	--	--	Green	--	--	--	
40		14 A u2	Sample	--	--	Green	36,73	32,30	2,37	
41		14 B u2	Sample	--	--	Green	--	--	--	
42		15 A u2	Sample	--	--	Green	--	--	--	
43		15 B u2	Sample	--	--	Green	36,65	32,30	2,35	
44		17 A u2	Sample	--	--	Green	36,25	32,30	2,07	
45		17 B u2	Sample	--	--	Green	--	--	--	
46		1 A u3	Sample	--	--	Green	34,81	32,40	2,08	
47		1 B u3	Sample	--	--	Green	35,67	32,30	2,10	
48		3 A u3	Sample	--	--	Green	--	--	--	
49		3 B u3	Sample	--	--	Green	--	--	--	
50		4 A u3	Sample	--	--	Green	37,74	32,30	2,33	
51		4 B u3	Sample	--	--	Green	35,70	32,30	2,12	
52		10 A u3	Sample	--	--	Green	30,50	29,80	2,05	
53		10 B u3	Sample	--	--	Green	34,10	32,40	2,06	
54		11 A u3	Sample	--	--	Green	32,13	31,70	2,10	
55		11 B u3	Sample	--	--	Green	34,52	32,40	2,04	
56		14 A u3	Sample	--	--	Green	33,50	32,40	2,10	
57		14 B u3	Sample	--	--	Green	--	--	--	
58		15 A u3	Sample	--	--	Green	34,78	32,40	2,10	
59		15 B u3	Sample	--	--	Green	--	--	--	
60		17 A u3	Sample	--	--	Green	--	--	--	
61		17 B u3	Sample	--	--	Green	--	--	--	
<input checked="" type="checkbox"/>	26		NTC LMP 1	NTC	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	27		Lmp1 3A U1	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	28		Lmp1 3A U3	Sample	--	--	Green	34,59	32,40	2,16
<input checked="" type="checkbox"/>	29		Lmp1 3B U1	Sample	--	--	Green	38,39	31,70	2,55
<input checked="" type="checkbox"/>	30		Lmp1 3B U3	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	31		Lmp1 4B U2	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	32		Lmp1 10A U2	Sample	--	--	Green	35,36	32,30	2,11
<input checked="" type="checkbox"/>	33		Lmp1 11B U2	Sample	--	--	Green	39,01	31,70	1,14
<input checked="" type="checkbox"/>	34		Lmp1 14B U2	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	62		Lmp1 14B U3	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	63		Lmp1 15A U2	Sample	--	--	Green	33,21	31,80	2,09
<input checked="" type="checkbox"/>	64		Lmp1 15B U1	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	65		Lmp1 15B U3	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	66		Lmp1 17A U1	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	67		Lmp1 17A U3	Sample	--	--	Green	38,42	31,90	1,93
<input checked="" type="checkbox"/>	68		Lmp1 17B U1	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	69		Lmp1 17B U2	Sample	--	--	Green	--	--	--
<input checked="" type="checkbox"/>	70		Lmp1 17B U3	Sample	--	--	Green	34,18	32,40	2,13

Lampiran 6. Hasil Pengolahan data dengan SPSS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
0=laki; 1=perempuan	.455	8	<.001	.566	8	<.001
0=kurang dari 41; 1=41-50; 2=51-60; 3=lebih 60	.371	8	.002	.724	8	.004
0=3;1=4A; 2=4B	.513	8	<.001	.418	8	<.001
0=who 3, 1= who2, 2=who1	.513	8	<.001	.418	8	<.001
0=normal; 1=90; 2=80	.325	8	.013	.665	8	<.001
0=komplit respon; 1= partial respon; 2=tidak respon	.455	8	<.001	.566	8	<.001

a. Lilliefors Significance Correction

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Exo_RNA_pre1	.221	8	.200*	.879	8	.184
Exo_RNA_pre2	.228	8	.200*	.869	8	.146
Exo_RNA_pre3	.231	8	.200*	.863	8	.127
Exo_RNA_post1	.206	8	.200*	.894	8	.256
Exo_RNA_post2	.206	8	.200*	.907	8	.331
Exo_RNA_post3	.299	8	.034	.847	8	.088
Pre_p53_ekson5_6	.233	8	.200*	.921	8	.438
Post_p53_ekson5_6	.137	8	.200*	.965	8	.859
Pre_p53_ekson4	.158	8	.200*	.936	8	.568
Post_p53_ekson4	.145	8	.200*	.963	8	.836
Pre_p53_ekson7	.513	8	<.001	.418	8	<.001
Post_p53_ekson7	.513	8	<.001	.418	8	<.001
Imp1_pre1	.418	8	<.001	.652	8	<.001
Imp1_pre2	.181	8	.200*	.957	8	.784
Imp1_pre3	.212	8	.200*	.953	8	.737
Imp1_post1	.401	8	<.001	.644	8	<.001
Imp1_post2	.351	8	.004	.690	8	.002
Imp1_post3	.378	8	.001	.665	8	<.001

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Paired Samples Test

		Mean	Std. Deviation	Std. Error Mean	Paired Differences		t	df	Sig. (2-tailed)
					95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Exo_RNA_pre1 - Exo_RNA_post1	10.77500	7.12435	2.51884	4.81889	16.73111	4.278	7	.004

Ranks

		N	Mean Rank	Sum of Ranks
Imp1_post1 - Imp1_pre1	Negative Ranks	3 ^a	3.00	9.00
	Positive Ranks	4 ^b	4.75	19.00
	Ties	1 ^c		
	Total	8		
Imp1_post2 - Imp1_pre2	Negative Ranks	3 ^d	7.00	21.00
	Positive Ranks	5 ^e	3.00	15.00
	Ties	0 ^f		
	Total	8		
Imp1_post3 - Imp1_pre3	Negative Ranks	5 ^g	5.60	28.00
	Positive Ranks	3 ^h	2.67	8.00
	Ties	0 ⁱ		
	Total	8		

- a. Imp1_post1 < Imp1_pre1
- b. Imp1_post1 > Imp1_pre1
- c. Imp1_post1 = Imp1_pre1
- d. Imp1_post2 < Imp1_pre2
- e. Imp1_post2 > Imp1_pre2
- f. Imp1_post2 = Imp1_pre2
- g. Imp1_post3 < Imp1_pre3
- h. Imp1_post3 > Imp1_pre3
- i. Imp1_post3 = Imp1_pre3

Test Statistics^a

	Imp1_post1 - Imp1_pre1	Imp1_post2 - Imp1_pre2	Imp1_post3 - Imp1_pre3
Z	-.845 ^b	-.420 ^c	-1.400 ^c
Asymp. Sig. (2-tailed)	.398	.674	.161

a. Wilcoxon Signed Ranks Test

b. Based on negative ranks.

c. Based on positive ranks.







Paired Samples Test

		Paired Differences				t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference Lower Upper			
Pair 1	Pre_p53_ekson5_6 - Post_p53_ekson5_6	.24625	1.24161	.43898	-.79176 1.28426	.561	7	.592
Pair 2	Pre_p53_ekson4 - Post_p53_ekson4	-.33125	.84279	.29797	-1.03584 .37334	-1.112	7	.303
Pair 3	Pre_p53_ekson7 - Post_p53_ekson7	.03625	.10253	.03625	-.04947 .12197	1.000	7	.351

Correlations

		Sigma_exosome	sigma_p53_1	Sigma_p53_2	Sigma_p53_3	Sigma_Imp1
Sigma_exosome	Pearson Correlation	1	-.147	-.368	-.238	-.256
	Sig. (2-tailed)		.728	.369	.571	.540
	N	8	8	8	8	8
sigma_p53_1	Pearson Correlation	-.147	1	.224	.083	-.077
	Sig. (2-tailed)	.728		.594	.846	.856
	N	8	8	8	8	8
Sigma_p53_2	Pearson Correlation	-.368	.224	1	.287	-.557
	Sig. (2-tailed)	.369	.594		.491	.152
	N	8	8	8	8	8
Sigma_p53_3	Pearson Correlation	-.238	.083	.287	1	-.349
	Sig. (2-tailed)	.571	.846	.491		.396
	N	8	8	8	8	8
Sigma_Imp1	Pearson Correlation	-.256	-.077	-.557	-.349	1
	Sig. (2-tailed)	.540	.856	.152	.396	
	N	8	8	8	8	8

Lampiran 7. Dokumentasi hasil pemeriksaan histopatologi subjek penelitian



Lampiran 8. Hasil pemeriksaan sekuensing produk PCR p53

Sampel no. 1 (post kemoradiasi)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cdsSequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1Range 1: 145 to 366 [GenBank](#) [Graphics](#)[▼ Next Match](#) [▲ Previous Match](#)

Score	Expect	Identities	Gaps	Strand
411 bits(222)	1e-110	222/222(100%)	0/222(0%)	Plus/Plus
Query 1	CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAGC	60		
Sbjct 145	CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAGC	204		
Query 61	GCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCCA	120		
Sbjct 205	GCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCCA	264		
Query 121	GGGTCCCAGGCCCTCTGATTCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCATC	180		
Sbjct 265	GGGTCCCAGGCCCTCTGATTCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCATC	324		
Query 181	TTATCCGAGTGGAAAGGAAATTTGCGTGTGGAGTATTTGGATG	222		
Sbjct 325	TTATCCGAGTGGAAAGGAAATTTGCGTGTGGAGTATTTGGATG	366		

Sampel no. 3 (pre kemoterapi)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cdsSequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1Range 1: 144 to 366 [GenBank](#) [Graphics](#)[▼ Next Match](#) [▲ Previous Match](#)

Score	Expect	Identities	Gaps	Strand
412 bits(223)	3e-111	223/223(100%)	0/223(0%)	Plus/Plus
Query 1	GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAG	60		
Sbjct 144	GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAG	203		
Query 61	CGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCC	120		
Sbjct 204	CGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCC	263		
Query 121	AGGGTCCCAGGCCCTCTGATTCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCAT	180		
Sbjct 264	AGGGTCCCAGGCCCTCTGATTCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCAT	323		
Query 181	CTTATCCGAGTGGAAAGGAAATTTGCGTGTGGAGTATTTGGATG	223		
Sbjct 324	CTTATCCGAGTGGAAAGGAAATTTGCGTGTGGAGTATTTGGATG	366		

Sampel no. 10 (pre kemoradiasi)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cds

Sequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1

Range 1: 144 to 366 [GenBank](#) [Graphics](#)

▼ Next Match ▲ Previous Match

Score	Expect	Identities	Gaps	Strand
407 bits(220)	2e-109	223/224(99%)	1/224(0%)	Plus/Plus
Query 1	GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGGA	60		
Sbjct 144	GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCAT-GA	202		
Query 61	GCGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCC	120		
Sbjct 203	GCGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCC	262		
Query 121	CAGGGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCA	180		
Sbjct 263	CAGGGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCA	322		
Query 181	TCTTATCCGAGTGGAAAGAAATTTGCGTGTGGAGTATTTGGATG	224		
Sbjct 323	TCTTATCCGAGTGGAAAGAAATTTGCGTGTGGAGTATTTGGATG	366		

Sampel no. 11 (pre kemoradiasi)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cds

Sequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1

Range 1: 146 to 365 [GenBank](#) [Graphics](#)

▼ Next Match ▲ Previous Match

Score	Expect	Identities	Gaps	Strand
407 bits(220)	2e-109	220/220(100%)	0/220(0%)	Plus/Plus
Query 1	CATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAGCG	60		
Sbjct 146	CATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAGCG	205		
Query 61	CTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCAG	120		
Sbjct 206	CTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCAG	265		
Query 121	GGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCATCT	180		
Sbjct 266	GGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCTCCTCAGCATCT	325		
Query 181	TATCCGAGTGGAAAGAAATTTGCGTGTGGAGTATTTGGAT	220		
Sbjct 326	TATCCGAGTGGAAAGAAATTTGCGTGTGGAGTATTTGGAT	365		

Sampel no. 11 (post kemoradiasi)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cds

Sequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1

Range 1: 145 to 365 [GenBank](#) [Graphics](#) [Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
409 bits(221)	4e-110	221/221(100%)	0/221(0%)	Plus/Plus
Query 1	CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGC	60		
Sbjct 145	CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGC	204		
Query 61	GCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCCA	120		
Sbjct 205	GCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCCA	264		
Query 121	GGGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCCTCCTCAGCATC	180		
Sbjct 265	GGGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCCTCCTCAGCATC	324		
Query 181	TTATCCGAGTGAAGGAAATTTGCGTGTGGAGTATTTGGAT	221		
Sbjct 325	TTATCCGAGTGAAGGAAATTTGCGTGTGGAGTATTTGGAT	365		

Sampel no. 14 (pre kemoradiasi)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cds

Sequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1

Range 1: 145 to 365 [GenBank](#) [Graphics](#) [Next Match](#) [Previous Match](#)

Score	Expect	Identities	Gaps	Strand
409 bits(221)	4e-110	221/221(100%)	0/221(0%)	Plus/Plus
Query 1	CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGC	60		
Sbjct 145	CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGC	204		
Query 61	GCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCCA	120		
Sbjct 205	GCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCCCA	264		
Query 121	GGGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCCTCCTCAGCATC	180		
Sbjct 265	GGGTCCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGTCTGGCCCCCTCCTCAGCATC	324		
Query 181	TTATCCGAGTGAAGGAAATTTGCGTGTGGAGTATTTGGAT	221		
Sbjct 325	TTATCCGAGTGAAGGAAATTTGCGTGTGGAGTATTTGGAT	365		

Sampel No. 14 (post kemoradiasi)

[Download](#) [GenBank](#) [Graphics](#)

Homo sapiens tumor suppressor p53 (TP53) gene, exons 5, 6 and partial cds

Sequence ID: [KM597769.1](#) Length: 436 Number of Matches: 1

Range 1: 144 to 366 [GenBank](#) [Graphics](#)

[▼ Next Match](#) [▲ Previous Match](#)

Score	Expect	Identities	Gaps	Strand
412 bits(223)	3e-111	223/223(100%)	0/223(0%)	Plus/Plus
Query 1	GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAG	60		
Sbjct 144	GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCACCATGAG	203		
Query 61	CGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCC	120		
Sbjct 204	CGCTGCTCAGATAGCGATGGTGAGCAGCTGGGGCTGGAGAGACGACAGGGCTGGTTGCC	263		
Query 121	AGGGTCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGCTGGCCCTCCTCAGCAT	180		
Sbjct 264	AGGGTCCCAGGCCTCTGATTCCCTCACTGATTGCTCTTAGGCTGGCCCTCCTCAGCAT	323		
Query 181	CTTATCCGAGTGAAGGAAATTTGCGTGTGGAGTATTTGGATG	223		
Sbjct 324	CTTATCCGAGTGAAGGAAATTTGCGTGTGGAGTATTTGGATG	366		